NDA 018963 · Bracco
Choletec
Technetium Tc-99m Mebrofenin Kit · Injection
NovelLast checked: Nov 20, 2026Latest source record: Sep 10, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Jan 21, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
92
31 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 29, 2025.
INDICATIONS AND USAGE Technetium Tc 99m Mebrofenin is indicated as a hepatobiliary imaging agent.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 21, 1987 Original approval · Type 1 - New Molecular Entity
1 products under this application
- CHOLETEC · TECHNETIUM TC-99M MEBROFENIN KIT N/A · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Mebrofenin Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug effect decreased34
- multiple use of single-use product29
- nausea10
- hypersensitivity6
- drug ineffective5
- vomiting5
- asthenia4
- chills4
- headache4
- therapeutic response unexpected4
- abdominal pain upper3
- diarrhoea3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 2 |
| 2013 | 13 |
| 2014 | 33 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2026 | 5 |
Recalls
1 FDA enforcement reports for this application.
Aug 14, 2012 · Class III · Terminated
Presence of Particulate Matter; potential for charcoal particulates
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Bracco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.